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Abstract
There is growing evidence that stem and progenitor cells exert regenerative actions by means of paracrine factors. In line with
these notions, we recently demonstrated that endothelial progenitor cell (EPC)-derived conditioned medium (EPC-CM)
substantially increased viability of brain microvascular cells. In the present study, we aimed at investigating whether EPC-CM
supports cell survival of cultured striatal progenitor cells. For that purpose, primary cultures from fetal rat embryonic (E14)
ganglionic eminence were prepared and grown for 7 days in vitro (DIV). EPC-CMwas administered from DIV5–7. Treatment of
the striatal cultures with EPC-CM resulted in significantly increased densities of GABA-immunoreactive (-ir) neurons. Inhi-
bition of mitogen-activated protein kinase and phosphatidylinositol-3-kinase, but not of the ROCK pathway, significantly
attenuated the EPC-CM induced increase in GABA-ir cell densities. Similar results were observed when EPC-CM was sub-
jected to proteolytic digestion and lipid extraction. Furthermore, inhibition of translation abolished the EPC-CM induced
effects. Importantly, EPC-CM displayed neuroprotection against 3-nitropropionic acid induced toxicity. These findings
demonstrate that EPC-derived paracrine factors substantially promote survival and/or differentiation of cultured striatal
progenitor cells involving both proteinaceous factors and lipidic factors. In sum, EPC-CM constituents might lead to a novel
cell-free therapeutic strategy to challenge neuronal degeneration.
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Introduction
Neurodegenerative diseases pose a growing burden and,
despite much effort, effective interventions are currently still
lacking. Progresses in stem cell research have raised the
prospect that nervous tissue might be regenerated by exploit-
ing the characteristic proliferative and differentiation prop-
erties of these cells. Stem cells are generally considered as a
tool for replacing injured cells, but increasing attention has
recently been given to the capacity of stem and progenitor
cells to secrete a wide array of factors. Indeed, it is the
humoral actions, rather than the transdifferentiation/
engraftment, of stem cells that are now believed to be the
main actors in the scenario of tissue regeneration. In this
regard, there is compelling evidence that paracrine factors
released by bone marrow-derived endothelial precursors
support the viability of different tissues1,2. We have previ-
ously shown that the endothelial progenitor cell (EPC)
“secretome” in the form of conditioned medium (EPC-
CM) has high tissue regenerative potential3–5. EPCs and
their soluble factors have also been used successfully in
traumatic brain injury, ischemic stroke, and white matter
damage models, but these effects have usually been
interpreted in the context of neurovascular repair2,6–8.
Moreover, transplantation of neuronal progenitors
from ganglionic eminence (GE) for the treatment of
1 Department of Neurosurgery, Bern University Hospital, Switzerland
Submitted: November 21, 2018. Revised: February 5, 2019. Accepted:
February 8, 2019.
Corresponding Author:
Hans R. Widmer, Department of Neurosurgery, Neurocenter and
Regenerative Neuroscience Cluster, Inselspital, Bern University Hospital,
University of Bern, 3010 Bern, Switzerland.
Email: hanswi@insel.ch
Cell Transplantation
2019, Vol. 28(4) 367–378





Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0
License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further
permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Huntington’s disease (HD) has shown encouraging results,
and great efforts are currently being exerted to improve
transplantation protocols in animal models of the disease9.
In the present work, we aimed to investigate the effect of
EPC-CMmore specifically on differentiating primary stria-
tal progenitor cells from rat fetuses. In particular, we ana-
lyzed whether EPC-CM might influence the yield and
survival of GABAergic neurons, and attempted to charac-




Time pregnant Wistar rats were purchased from Janvier Labs
(Le Genest-Saint-Isle, France) and housed in a 12-hour light-
dark cycle with food and water ad libitum. All experiments
were carried out in the light phase and in accordance with the
guidelines of the Animal Research Ethics Committee of
Canton Bern, Switzerland, and the University of Bern Ani-
mal Care and Use Committee, Switzerland (study No. 6/12
and 10/15).
Preparation and Culture of Rat Dissociated Fetal GE
Cultures
GE cultures were prepared from embryonic day 14 (E14) rat
fetuses as described previously10. In brief, pregnant Wistar
rats were anesthetized using gas inhalation (4.5–5% isoflur-
ane, 75% N2O, 20% O2; Peachtree Corners, GA, USA) fol-
lowed by an i.p. injection of a mix of ketamine (120 mg/kg;
Vetoquinol AG, Ittigen, Switzerland) and xylaxine (20 mg/
kg; Vetoquinol AG). The fetuses were separated by caesar-
ean section and the dams decapitated and exsanguinated
immediately thereafter. The fetuses were then euthanized
by decapitation and the GE dissected out of the brain using
a stereoscopic microscope. The GE explants were disso-
ciated mechanically and plated at a density of 0.5
embryos/well (seeding density of 600 viable cells per
mm2) into 24-well plates with a glass insert (glass coverslips
of 12 mm diameter, Assistent, Sandheim, Germany) pre-
coated with poly-L-lysine (0.1 mg/mL; Sigma, Buchs, Swit-
zerland). Each well contained 0.5 ml of culture medium
containing 55% Dulbecco’s modified eagle medium
(DMEM), 32.5% Hank’s balanced salt solution (HBSS;
Gibco, Reinach, Switzerland), 0.3% glucose, 10% fetal calf
serum (FCS; Gibco, Reinach, Switzerland) and 1% 0.01 M
HEPES (Merck, Darmstadt, Germany) as well as antibiotics/
antimycotics (061-05240 D; Gibco, Reinach, Switzerland).
The medium was refreshed after 2 days in vitro (DIV) and
exchanged at DIV5 to the different treatment groups, as
described below, for another 2 days. At the end of the experi-
mental period, at DIV7, the cultures were washed with phos-
phate buffered saline (PBS) and processed for the different
analyses as described below.
EPC Culture and CM Preparations
EPC were isolated from peripheral blood mononuclear cells
from healthy human anonymous donors as previously
described11. The buffy coats employed for this procedure
were purchased from the Interregional Transfusion Centre
of the Swiss Red Cross (Bern, Switzerland), and no experi-
mental approval or informed consent was needed. Moreover,
all samples were handled according to the regulations and
guidelines of the University Hospital Bern. Mononuclear
cells were prepared by centrifugation through a density gra-
dient on Lymphoprep (Axis-Shield, Dundee, UK) and plated
on fibronectin (Sigma, Buchs, Switzerland)-coated 6-well
plastic dishes (Falcon) at a density of 1 million cells/cm2
using endothelial cell basal medium-2 (EBM-2) (Lonza,
Basel, Switzerland) supplemented with endothelial growth
medium BulletKit and 5% FBS (Lonza, Basel, Switzerland).
After 4 days in culture, adherent cells were passaged at a
density of 0.1 million cells/cm2 and cultured through day 7
to obtain early outgrowth EPC. To produce EPC-CM, EPC
were incubated for 48 hours under hypoxic conditions (1.5%
O2, 5% CO2, 93.5% N2) using a humidified gas-sorted anoxic
incubator-gloved box (InVivo2 400, Ruskinn Technologies,
Bridgend, UK) in growth factor-free EBM-2 containing 1%
FBS since we have previously observed that these culture
conditions enhance soluble factor secretion by EPC3. After
incubation, EPC-CM was collected and centrifuged at 1000
rpm at 4C, the supernatant was sterile filtered and snap-
frozen until use3. The EBM-2 containing 1% fetal bovine
serum (FBS) was treated in parallel to the cell cultures and
served as control medium (unconditioned medium). Through-
out all the experiments, EPC-CM and control medium were
processed simultaneously with the same treatments.
Conditioned Medium Treatments
To eliminate the proteinaceous content in the CM, the CM
was treated with proteinase K as described earlier5,12. In
brief, aliquots of EBM-2 or CM medium were incubated
with agarose beads-proteinase K (Sigma, Buchs, Switzer-
land; 5 U) in 15 ml polypropylene test tubes (BD Falcon,
Allschwil, Switzerland) for 4 h at 37C in a rotating roller
drum. Thereafter, the tubes were centrifuged 5 min at 2000
rpm to pellet the agarose beads-proteinase K, and the pro-
teinase K-free supernatant was carefully collected and used
for subsequent experiments. The treatment resulted in degra-
dation of proteins as assessed in Coomassie Blue (Sigma,
Buchs, Switzerland)-stained gels5,12 (Fig. 1).
Control medium and EPC-CM were treated with chloro-
form as previously described5,13 to remove the lipidic com-
ponents. In brief, EBM-2 or CM medium was mixed with
equal volumes of chloroform. Thereafter, the medium was
centrifuged for 5 min at 3000 rpm, the aqueous phase
was collected and the procedure was repeated. The medium
was then transferred into an open 1 cm Petri dish and the
traces of chloroform were left to evaporate in the sterile hood
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for 10 min. Finally, the volume of water lost due to the
evaporation was reconstituted with distilled sterile water.
Treatments
Culture wells were assigned randomly to the different treat-
ment groups and incubated from DIV5 until the end of the
experimental period at DIV7. To investigate the effects of
CM on GE cultures, CM was added to the cultures and
compared to control cultures treated with EBM-2. To further
investigate the potential signaling involved in the effects
observed in the first experiments, the specific phosphoinosi-
tide-3-kinase/activated kinase (PI3K/AKT) inhibitor
LY294002 (Gibco, Reinach, Switzerland) (10 mM), the spe-
cific mitogen-activated protein kinase kinase/extracellular
regulated kinase (MEK/ERK) inhibitor PD98059 (Gibco,
Reinach, Switzerland) (10 mM) and the selective Rho-
associated coiled-coil containing kinases (ROCK) inhibitor
Y27632 (Sigma, Buchs, Switzerland) (10 mM) were added
30 min prior the treatment with EBM-2 and EPC-CM,
respectively. To investigate whether translation might inter-
fere with EPC-CM mediated effects on GABA-ergic cell
density cycloheximide (Sigma, Buchs, Switzerland) (10
mM) was added to the culture medium at DIV5 with or
without concurrent EPC-CM addition. Moreover, based on
our results of EPC-CM mediated effects on microvascular
endothelial cells5, we investigated whether the observed
effects after EPC-CM treatment are attributed to the lipidic
or the proteinaceous content of the EPC-CM. For that
purpose, cultures were treated with chloroform-extracted
EPC-CM and proteinase-K-treated EPC-CM, EBM-2 was
exposed to the same treatments and served as controls.
The effects on neuroprotection were assessed by the treat-
ment of the cultures with 3-nitropropionic acid (3-NP;
Sigma, Buchs, Switzerland; 5 mM) from DIV5-7 in combi-
nation with either EBM-2 or EPC-CM. In addition, we tested
whether exposure of cultures to EPC-CM from DIV2-5 prior
to the insult altered the effects during the 3-NP treatment.
3-NP is an irreversible inhibitor of mitochondrial respiratory
complex II succinate dehydrogenase, resulting in energy
depletion through disruption of the electron transport chain
and eventually in the death of GABA-ergic neurons that
closely mimics HD neuropathology14–16.
Cell Viability Assay
Cell viability was assessed as previously described with
minor modifications4. Briefly, cultures were treated as
described above. At DIV7, the experimental media were
replaced with incubation medium and the number of viable
cells was assessed by the Presto Blue assay (Invitrogen,
Reinach, Switzerland) using a microplate reader (Ex. 560
nm, Em. 590 nm; VarioSkan, ThermoFisher Scientific, Rein-
ach, Switzerland).
Western Blotting and Protein Measurements
The cells were lysed in RIPA buffer (ThermoFisher Scien-
tific, Reinach, Switzerland) containing protease inhibitor
cocktail set V (Sigma, Buchs, Switzerland), 1 mM phenyl-
methylsulfonyl fluoride (PMSF, Sigma, Buchs, Switzerland)
1 mg/ml leupeptin (Sigma, Buchs, Switzerland) and 1 mM
sodium orthovanadate (Sigma, Buchs, Switzerland). The
protein concentration was determined in two aliquots per
lysate using the Pierce BCA Protein Assay Kit (Thermo-
Fisher Scientific, Reinach, Switzerland). Total protein con-
tent in control cultures was 355.8+ 7.1 mg per culture. The
Western blotting was carried out according to the method of
Laemmli17 with some modifications. Equal amounts of the
proteins were run on a 12% polyacrylamide gel and trans-
ferred to a PVDF membrane (Bio-Rad Laboratories AG,
Cressier, Switzerland). The transfer efficiency was checked
by Coomassie Blue staining of the gels. Blots were blocked
for 45 min in 5% fat-free milk powder in TBS-Tween 0.01%
and incubated with the same solution overnight with primary
antibodies (mouse anti-glial fibrillary acidic protein (GFAP),
1:500, Millipore, Zug, Switzerland; mouse anti-proliferating
cell nuclear antigen (PCNA), 1:1000, Sigma, Buchs,
Switzerland; rabbit anti-a-tubulin, 1:2000, Sigma, Buchs,
Switzerland). After washing in TBS-Tween 0.01% the blots
were incubated for 1 h with antibody-peroxidase conjugates
(anti-mouse or anti-rabbit, 1:10,000; Jackson ImmunoRe-
search, Ely, UK) in 5% fat-free milk powder in TBS-
Tween 0.01%. Subsequent to washing the blots were
visualized with the enhanced chemiluminescence substrate
kit (ThermoFisher Scientific, Reinach, Switzerland) using
Fig. 1. Representative SDS-PAGE of untreated and proteinase K-
treated (prot-K) control (Ctrl) and EPC-CM media stained with
Coomassie Blue. Note that protein signals including BSA (arrow-
head) are significantly reduced in both media after 4 h of proteinase
K-treatment.
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the Fusion Pulse TS System (Vilber Lourmat, Colle´gien,
France). Bands were quantified on 8bit converted images
using the Fiji software and normalized against a-tubulin.
Eight cultures from four independent experiments were
included for the analyses.
Immunocytochemistry
To visualize GABAergic neurons, the cell cultures were fixed
for 30 min in 4% paraformaldehyde, washed and blocked with
10% horse serum in 0.1% Triton-X-100/PBS. Thereafter, the
cells were incubated overnight with the primary antibody
rabbit anti-GABA (1:5000; Sigma, Buchs, Switzerland) in
0.1% Triton-X-100/PBS with 2.5% horse serum at 4C. Sub-
sequent to washes in PBS, the cultures were incubated for 2 h
with biotinylated anti-rabbit IgG (1:200, Vector Laboratories,
Servion, Switzerland). Endogenous peroxidase was blocked
for 10 min in 3% hydrogen peroxide and 10% methanol in
PBS. Bound antibodies were visualized after washes in PBS
by the avidin-biotin complex (VECTASTAIN® ABC-
Peroxidase Kit; 1:250, PK-4000; Vector Laboratories, Ser-
vion, Switzerland) in combination with the DAB Substrate
Kit (34002, ThermoFischer Scientific). The cultures were
mounted with Aquatex (Millipore, Darmstadt, Germany).
For the analysis of mature neurons the cultures were
stained for the general neuronal marker neuronal nuclei
(NeuN). Cultures were treated as described above and incu-
bated overnight at 4C with the primary antibody mouse
monoclonal anti-NeuN (1:500, Millipore, Zug, Switzer-
land). Subsequent to washes in PBS, the cultures were incu-
bated for 2 h with the fluorescently labelled antibody
Alexa® Fluor donkey anti-mouse 488 nm 1:250, Molecular
Probes, Carlsbad, CA, USA). Cultures were then washed
for 4  10 min in PBS and mounted in 0.1 M PBS contain-
ing 50% glycerol.
Histological Analyses
All cultures were analyzed under bright field illumination by
a researcher blinded to the treatment groups as described by
our group before18–22. In brief: only cells with distinct
immunoreactivity, clear neuronal shape, and visible neurites
were counted as GABA-positive neurons. To obtain cell
counts, 5.2% of the glass slide surface (113 mm2) in the
culture dish was analyzed in six areas (in the upper, right,
lower, left corners (distance 2.5 mm from edge) and twice in
the center of the culture; each sized 0.97mm2) using an X10
objective in combination with an X10 ocular with counting
grid (100 magnification). If there was any doubt about the
specification of GABA-ir neurons, the cell cultures were
examined at a higher magnification (400). Cell density was
calculated per square millimeter (mean density in control
cultures for GABA-ir neurons was 80.2 + 5.8 cells per
mm2). For the determination of GABA-ir cell densities after
control and EPC-CM treatment alone, 85 and 79 cultures,
respectively, were analyzed from nine independent
experiments. For the analyses with drug treatments, 7–16
cultures per group were included from two to four indepen-
dent experiments. Fluorescence pictures stained for NeuN
(12 and 11 cultures from control and EPC-CM treatment,
respectively; four independent experiments) were recorded
using an Olympus epifluorescence microscope (BX51,
Olympus, Tokyo, Japan) equipped with a digital camera
(Olympus DP72, Olympus, Tokyo, Japan). NeuN-ir cell
counts were analyzed in six areas (in the upper, right, lower,
left corners (distance 2.5 mm from edge) and twice in the
center of the culture; each sized 0.15 mm2) using an X20
objective (200 magnification). Cell density was calculated
per square millimeter (mean density in control cultures for
NeuN-ir cells was 118.2+ 5.6 cells per mm2).
Statistical Evaluation
For statistical analysis, a commercially available software
package was used (Prism 7.04, GraphPad Software, La Jolla,
CA, USA). To compare group means of several groups,
one-way analysis of variance (ANOVA) followed by
Newman-Keuls multiple comparison test was used. Statistical
significance of two groups only was assessed by two-tailed
unpaired t-test or by the non-parametric Mann-Whitney test
based on the outcome of the D’Agostino & Pearson normality
test. Differences were considered statistically significant at
p < 0.05. Data are presented as mean þ SEM.
Results
Effect of EPC-CM Treatment on GABA-ir Cell Densities
in Dissociated GE Cultures
Cultures were grown for 7 DIV and exposed to the EPC-CM
from DIV5–7. We observed that the density of GABA-ir
neurons was significantly higher in EPC-CM-treated striatal
cultures as compared to controls (by 41.4% + 4.7%, p 
0.0001) (Fig. 2). Similarly, the density of NeuN-ir neurons
was significantly augmented after EPC-CM exposure (by
44.5+ 17.7%, p 0.003) (Fig. 3). In line with these results,
the striatal cultures treated with EPC-CM disclosed a signif-
icantly higher protein content compared to controls (by 1.33
fold, t2.4/14, p < 0.05) (Fig. 4A) as well as a slight but sig-
nificant increase in number of viable cells (t2.07/46, p << 0.05)
(Fig. 4B). EPC-CM treatment resulted in a slight increase in
GFAP levels (by 1.3-fold); however, this did not reach sta-
tistical significance (Fig. 4C). Finally, EPC-CM administra-
tion from DIV5-7 induced significantly higher levels of
PCNA (by 1.46-fold, t2.3/12, p < 0.05) (Fig. 4D).
EPC-CM Mediated Effects on GABA-ir Neurons Involve
the ERK/MAPK and the AKT/PI3K Pathways
In our previous work, we reported that the ERK/MAPK and
AKT/PI3K pathways are involved in mediating the angio-
genic effects of EPC-CM on brain microvascular endothelial
cells4. We therefore tested whether these pathways are
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implicated in the augmented GABA-ir cell densities
observed after EPC-CM treatment. We found that the com-
bined administration of the specific MEK/ERK inhibitor
PD98059 resulted in a decrease in GABAergic cell densities
as compared to EPC-CM treatment alone (F (3,52)¼ 5.45; p
< 0.005) (Fig. 5A). Similarly, exposure of the cultures with
the specific AKT/PI3K inhibitor LY294002 concomitantly
with the EPC-CM treatment resulted in a reduction of
GABAergic cell densities as compared to EPC-CM treat-
ment alone (F (3,41) ¼ 5.34; p < 0.005) (Fig. 5B). On the
other hand, the ROCK pathway was not involved in the
effects on GABA-ir cell densities observed after EPC-CM
treatment. So, exposure of cultures with the selective ROCK
inhibitor Y0503 and EPC-CM resulted in significantly
higher as compared to controls (F (3,38) ¼ 6.97; p <
0.001) (Fig. 5C).
EPC-CM Mediated Effects are Dependent on
Translational Processes
In order to investigate whether translational processes were
involved in the EPC-CM-induced higher GABA-ir cell densi-
ties, striatal cultureswere exposed to the specific protein synth-
esis inhibitor cycloheximide (10 mM) from DIV5–7 in the
absence or presence ofEPC-CM. Inhibitionof translation abol-
ished the increase in densities of GABA-ir neurons after
EPC-CM administration (F (3,22)¼ 16.04; p < 0.001) (Fig. 6).
Both Proteinaceous Factors and Lipidic Factors
Contribute to the Increased GABA-ir Cell Numbers
After EPC-CM Administration
EPC-CM contains a wide variety of growth factors and
cytokines4,5. Hence, we aimed to assess whether the pro-
teinase K treatment exerted an effect of the actions of EPC-
CM. The higher GABA-ir cell densities induced by native
EPC-CM was completely abrogated by the proteinase K
treatment (F (3,31) ¼ 15.25: p < 0.001) (Fig. 7A). Similar
to the outcome seen for proteinase K treatment, removal of
lipids from EPC-CM significantly diminished EPC-CM
mediated effects on GABA-ir cell densities (F (3,28) ¼
5.47; p < 0.005) (Fig. 7B).
EPC-CM Exerts Neuroprotection Against 3-NP-Induced
Toxicity
To investigate if EPC-CM treatment exerts neuroprotective
actions against an insult, cultures were exposed to the toxin
Fig. 2. Representative photomicrographs of GABA-ir neurons in fetal rat striatal cultures grown for 7 days in vitro (DIV) treated (A) without
or (B) with endothelial progenitor cells secretome (EPC-CM) from DIV5-DIV7. Scale bars: 100 mm, 25 mm (insets).
Fig. 3. Representative photomicrographs and quantitative analysis of NeuN-ir neurons in fetal rat striatal cultures grown for 7 days in vitro
(DIV) treated without (Ctrl, open bar) or with EPC-CM (filled bar) from DIV5 to DIV7. Scale bar: 50 mm. Data are presented as a percentage
of controls and values given as mean þ SEM. *p < 0.05.
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3-NP, alone or in combination with EPC-CM. As excepted,
EPC-CM treatment significantly elevated GABA-ir cell den-
sities, while exposure to the toxin 3NP significantly reduced
GABA-ir cell densities as compared to controls (F (3,41) ¼
8.372; p < 0.001) (Fig. 8). Notably, the presence of EPC-CM
during the insult resulted in a significant protection of the
GABA-ir cell densities and presented as in controls (Fig. 8).
EPC-CM exposure of cultures prior to the 3-NP treatment
did not further alter the neuroprotective effects of EPC-CM
on GABA-ir cell densities (Fig. 9A). In contrast, we detected
that EPC-CM pretreatment resulted in significantly higher
viable cell numbers as compared to the non-pretreated cul-
tures after 3-NP exposure (F (2,30) ¼ 12.52; p < 0.0001)
(Fig. 9B).
Fig. 4. Quantitative analysis of (A) total protein content, (B) viable cell number and (C, D) Western blot quantification of GFAP (C) and
PCNA signals (D) in the striatal fetal cultures. Cultures were grown for 7 DIV and treated without (Ctrl) or with EPC-CM from DIV5 to
DIV7. Data are presented as a percentage of controls and values given as mean þ SEM. *p < 0.05 versus corresponding control.
Fig. 5.Quantitative analysis of GABA-ir cell densities in the striatal fetal cultures. Cultures were grown for 7 DIV. The drugs PD98059 (PD;
[10 mM]), LY294002 (LY; [10 mM]) and Y0503 (Y; [10 mM]) were added at DIV5–DIV7 concomitantly with EPC-CM. Untreated cultures
served as controls (Ctrl). Note that the exposure to the inhibitors of the MEK/ERK (A) and the PI3K/AKT (B) pathways significantly reduced
the EPC-CM induced higher GABAergic cell densities while the inhibitor of the ROCK pathway did not (C). Data are presented as a
percentage of controls and values given as mean þ SEM. *p < 0.05 versus corresponding controls.
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Discussion
The remarkable angiogenic capacity of EPC has been docu-
mented extensively11,23–25, and these beneficial effects can
be positively explained by the fact that the maintenance of a
functional vascular network is essential for the delivery of
nutrients, signaling molecules, and cells at the site of tissue
injury. Observations made in the last decade suggest that
EPC regenerative action might extend beyond vascular tis-
sue26–28. In line with this notion, there is mounting evidence
that EPCs release a wide array of factors, including growth
factors, cytokines, lipids, and extracellular matrix, which
play a crucial role in supporting tissue viability and evoke
a regenerative response8,29–31. Currently, the concept of
engraftment/transdifferentiation has been revisited, and the
paracrine actions and induction of humoral effects in the host
tissue are considered to be mainly responsible for the ther-
apeutic effects of transplanted EPC32.
Preclinical studies have demonstrated that EPC paracrine
factors, in the form of CM, can be exploited as a therapeutic
tool (for a comprehensive review see33); EPC-CM has been
shown to relieve the ischemic injury in skeletal and myocar-
dial muscle3,31,34,35. More recently, EPC-CM displayed pro-
mising neuroprotective potential for ischemic stroke36,37,
promoted the dopaminergic phenotype in neuronal stem
cells cultures38, and increased the number of doublecortin
positive neuronal precursors in the subventricular zone of
adult rats39. To the best of our knowledge, the present study
is the first that specifically addresses the effects of EPC-CM
on developing striatal cells, and attempts to characterize the
cellular mechanisms involved.
The observed increase in densities of GABA-ir neurons in
our experimental settings can be due to different mechan-
isms, i.e., a higher proliferation rate of neuronal progenitor
cells and/or an increased survival and differentiation. That
EPC-CM induced cell proliferation in our cultures is sup-
ported by the results of Western blot analysis for the general
cell proliferation marker PCNA; however, it seems unlikely
that this observation accounts for the increased GABAergic
cell densities seen after the 2-day treatment. The finding that
Fig. 6. Effects of EPC-CM treatment on cell densities of GABA-
immunoreactive (-ir) neurons in striatal cultures exposed to cyclo-
heximide. Cultures were grown for 7 DIV and exposed to
cycloheximide [10 mM] from DIV5-7 in the absence (open bar) or
presence of EPC-CM (filled bar). Untreated cultures served as
controls (Ctrl). Note that the treatment with cycloheximide fully
abolished the EPC-CM induced higher GABA-ir cell densities. Data
are presented as a percentage of controls and values are given as
mean þ SEM. *p < 0.05 versus control.
Fig. 7. Effects of the protein content (by means of proteinase K
digestion, prot-K; A) and of the lipids content (by means of chloro-
form extraction, chloro; B) from control medium (Ctrl) and EPC-
CM on GABA-ir cell densities in fetal striatal cultures. Cultures
were grown for 7 DIV and exposed to the modified EPC-CMs from
DIV5 to DIV7. Note that both the inactivation of proteins and the
removal of lipids of the EPC-CM resulted in significantly lower
GABA-ir cell densities as compared to EPC-CM alone. Data are
presented as a percentage of controls and values given as mean þ
SEM. *p < 0.05 versus corresponding controls; #p < 0.05 versus
EPC-CM treated cultures.
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total protein content was significantly higher in the EPC-CM
treated samples may hint to the notion that EPC-CM also
increased numbers of other neuronal populations as well as
other cell types. The former is corroborated by the observa-
tion of significantly higher numbers of NeuN-ir cells in EPC-
CM treated cultures. In addition, Western blot analysis
showed a tendency for GFAP to be higher in treated cultures,
possibly also reflecting effects on glial cell populations.
However, we did not specifically investigate these issues
after the initial observations, but rather focused on charac-
terizing the general factors, i.e. proteinaceous and lipidic,
and signaling pathways involved in the EPC-CM-mediated
increased densities of GABA-ir neurons.
In line with our previous observations in endothelial
cells4, the response of striatal neurons to EPC-CM is modu-
lated by activation of the PI3K/AKT and MAPK/ERK cas-
cades. Interestingly, also creatine administration promoted
GABAergic phenotype in striatal cultures through PI3K/
AKT and MAPK/ERK40. The involvement of PI3K/AKT
and MAPK/ERK in EPC-CMmediated effects is not surpris-
ing given the presence of several growth factors, e.g. brain-
derived neurotrophic factor (BDNF) glial cell line-derived
neurotrophic factor (GDNF), neuritin and vascular endothe-
lial growth factor VEGF, known to be potent inducers of
these signaling pathways41–44. In the central nervous system
AKT/PI3K signaling is important in regulating the survival
and development of neurons. Furthermore, AKT/PI3K sig-
naling provides neuroprotection against various stresses,
including oxidative stress in the adult brain by blocking
pro-apoptotic mechanisms (for review see Zhong45) while
ERK activation by small molecules exerts neuroprotection in
vitro and in vivo models of HD46. Nevertheless, direct evi-
dence by means of blocking antibody experiments for each
of the potentially active neurotrophic factors mentioned
above is necessary to prove their involvement in EPC-CM
mediated effects. Inhibition of the ROCK pathway did not
abolish the effects on GABA-ir cell densities after EPC-CM
treatment. ROCK has been associated with neurite out-
growth, dendritic branching, and spine formation, which are
all markedly inhibited when constitutively activated RhoA is
expressed (for review see Amano et al.47).
The observation that inhibition of translation by means of
the protein translation inhibitor cycloheximide interfered
with the actions of the EPC-CM may indicate that at least
some of the effects were mediated indirectly, e.g. by produc-
tion of growth factors acting in autocrine signaling. In line
with this assumption, it has been reported that the translation
of BDNF was increased in hippocampal neurons after acti-
vation by glutamate and BDNF itself and that this involved
multiple signaling cascades, including RAS–ERK48,49.
The encouraging results concerning the use of stem cells
secretomes on different clinical conditions has stimulated
investigations aimed at the identification of the components
of this vast collection of bioactive molecules. Proteomics
studies have generated detailed maps of the peptides present
in EPC-CM29,31; however, comprehensive analyses of the
population of lipidic factor released by these cells have not
yet been performed. Though it is known that EPC release
prostaglandins50, it can be excluded that this class of lipids
contributed to the effect of EPC-CM described in our work
since they are not extractable by chloroform51. Importantly,
it has been reported that bone marrow progenitor cells (a
class of cells that includes EPC), and mature endothelial
cells, secrete sphingosine-1-phosphate (S1P)52, and its
release is raised under hypoxic conditions. S1P is of partic-
ular interest as it is involved in neuronal differentiation
through direct53 and indirect mechanisms involving astro-
cytes54. However, at present, the possible presence and role
of S1P in EPC-CM can only be speculated on. Moreover, it is
now clear that proteins and lipids can be found in EPC-CM
not only as free soluble molecules but also shuttled together
with microRNA in exosomes and microvesicles27,55. Thus,
taking in consideration the possible interactions among the
different factors and their multiple modes of action, deci-
phering the overall secretome landscape will be a very
complex task, although efforts in this direction have been
taken for some exosomal cargoes56. In the present study,
we have chosen to limit our investigation to the biochem-
ical nature of the factors in EPC-CM able to modulate the
yield of GABAergic cells. The significantly reduced
GABA-ir cell densities following the proteolytic digestion
and lipid removal treatments of EPC-CM demonstrates that
both types of factors contribute to the EPC-CM effects.
Lipids might serve as signaling molecules and energy sub-
strates57, and which of the two functions were impaired by
the treatments of EPC-CM was not addressed in our
Fig. 8.Quantitative analysis of GABA-ir cell densities in the striatal
fetal cultures. Cultures were grown for 7 DIV. The drug 3-
nitropropionic acid (3-NP, [5 mM]) was added at DIV5–DIV7 in
absence (controls, Crtl) or presence of EPC-CM (EPC-CM þ 3-
NP). Data are presented as a percentage of controls and values are
given as mean þ SEM. *p < 0.05 versus control; #p < 0.05 versus 3-
NP and EPC-CM treated cultures.
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experimental setup. It cannot be excluded that chloroform
treatment affected also the exosomes eventually present in
our EPC-CM preparations.
Importantly, EPC-CM exerted neuroprotection against
the irreversible succinate dehydrogenase inhibitor 3-NP—
an observation that may be of importance in the context of
neurodegenerative disorders with impaired energy metabo-
lism due to a reduced mitochondrial complex-II and com-
plex-III58,59. Interestingly, exposure to EPC-CM prior to the
insult significantly augmented the cytoprotective effect on
viable cell numbers, while there was no effect seen when
assessing density of GABA-ir neurons. This likely reflects
that EPC-CM mediated also cytoprotective actions for addi-
tional cells subpopulations in the striatal cultures. Support
for this notion is given by the work of Fink and co-workers,
who reported that 3-NP also shows toxicity for cultured
hippocampal, septal, and hypothalamic neurons60.
In sum, the present work provides evidence that EPC-
derived CM is able to directly support the survival of
striatal progenitor cells. Moreover, our results show that
these actions are mediated by lipidic and proteinaceous
factors and involve the PI3K/AKT and MAPK/ERK sig-
naling pathways. Importantly, we could demonstrate that
EPC-CM is neuroprotective against 3-NP toxicity. In con-
clusion, our results suggest that EPC-CM might be useful
to expand the repertoire of available tools to tackle neuro-
nal degeneration.
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